TEMENOS
21.1.2021 08:32:10 CET | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, announced that it has exceeded 60 challenger bank clients confirming its status as the technology provider of choice for this growing segment. With the rich functionality of Temenos’ integrated front-to-back SaaS offering, challenger banks can launch rapidly, scale fast, provide differentiated services to customers and grow profitably.
A raft of digital banks – such as Alba , Alpian , Banco del Sol , Flowe , FlowBank, Lunar , Next Commercial Bank , Pepper, Varo Bank and WeLab Bank – have selected Temenos’ cloud-native, cloud-agnostic technology, joining the 3000+ Temenos customers around the globe including 41 out of the top 50 banks that run Temenos. News of Temenos exceeding the 60-bank milestone comes as the company launches new functionality designed specifically to cater to this fast-growing segment.
Temenos Infinity helps challengers deliver frictionless onboarding experiences for SMEs, while offering robust protection from fraud with financial crime mitigation, risk and compliance software. These enhancements directly address the need – which increased during the pandemic – for banks to offer more products and services to SMEs digitally through multiple channels. Risk and compliance is a significant area of focus for banks because the vetting process and credit decision-making takes place digitally. Temenos also offers Explainable AI models to allow banks to accelerate digital onboarding, conduct eligibility checks and process loans for SMEs to help them access funding faster. Temenos Infinity cuts the time to onboard SMEs by up to 75%, strengthening their relationship with the bank.
The multi-currency account is a new feature within Temenos Transact, the market-leading core banking product. Temenos multi-currency account is designed to be used like a current account allowing day-to-day transactions in many foreign currencies. This highly competitive product is aimed at customers who want to save in a foreign currency, receive money in multiple currencies, use their card in different countries and manage properties abroad. This functionality enables challengers to offer differentiated services and has already been adopted by digital banks such as Alpian and Flowbank.
Temenos’ Sandbox gives banks self-service access to experience the modern technology and functionality. Sandbox empowers challenger banks to adopt a growth-oriented, early-stage strategy to launch products incrementally and validate new propositions with their customers. With Sandbox, challengers can innovate using Temenos’ SaaS-first, cloud-agnostic technology.
Challenger banks benefit from Temenos’ pre-configured platform with pre-packaged products and services. Temenos Country Model Banks provides localized banking functionality from account opening to lending and mortgages, including local and regulatory compliance requirements, allowing challengers to deploy the technology faster without customization. This reduces development time and accelerates time to market. Temenos also enables banks to deploy an elastically scalable full stack solution across multiple cloud providers.
Temenos SaaS technology enables challengers to elastically scale based on business demand and service new customers at any growth rate. Challenger banks can create hyper-efficient cost models and in turn pass on the benefits to their customers. Varo Bank , for example, estimates that it services customers at 25% of the total costs incurred by a traditional bank.
Max Chuard, Chief Executive Officer, Temenos, said: “We see great traction globally where challenger banks – free from the constraints of legacy technology – recognize the potential for Temenos’ advanced technology. I am proud that with our modern technology we have been helping challengers especially ruing the pandemic to bring new products to market faster, be more agile and grow profitably. Temenos has a relentless focus on innovation and is investing over USD 1bn in R&D in the next few years. With Temenos’ cloud-native technology, challengers benefit from lower total cost of ownership and agility, rapid innovation and can offer outstanding banking experiences.”
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210120005600/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
